Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes

Masao Yamada, S. Hudson, O. Tournay, S. Bittenbender, S. S. Shane, B. Lange, Y. Tsujimoto, A. J. Caton, G. Rovera

Research output: Contribution to journalArticle

249 Citations (Scopus)

Abstract

Approximately 80% of hematopoietic malignancies of the B-cell lineage carry only one or two immunoglobulin heavy chain gene rearrangements indicating their clonal origin. These rearrangements due to the recombination of various variable, diversity, and joining regions of the heavy-chain gene segments during B-cell commitment result in a region called complementarity-determining region III (CDR-III). This region, which encompasses the diversity region of the heavy-chain segment, because of extensive somatic mutations, provides a DNA-encoded signature specific for each B-cell clone. CDR-III sequences were obtained from DNA of pre-B-cell acute lymphoblastic leukemia by using suitable primers and the polymerase chain reaction. The sequences were used to generate diagnostic probes that hybridized only to the amplified CDR-III of leukemic cells from which the sequences were derived. With these probes, leukemic cells could be detected when diluted 1:10,000 with other cells. By cloning the amplified CDR-III into recombinant libraries residual leukemic cells were accurately quantitated in bone-marrow samples from repeated relapses and remissions in one case of acute lymphoblastic leukemia. During a clinical remission lasting > 7 mo, malignant cells were present in marrow at > 1 per 1000 cells. These findings indicate that custom-made diagnostic probes will be useful in accurate quantitation of malignant cells in acute lymphoblastic leukemia patients in clinical remission and will allow investigation of the biological significance of low or high numbers of residual leukemic cells in evolution of that disease.

Original languageEnglish
Pages (from-to)5123-5127
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume86
Issue number13
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

Complementarity Determining Regions
Cell Lineage
Hematologic Neoplasms
B-Lymphocytes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Immunoglobulin Heavy Chain Genes
B-Lymphoid Precursor Cells
Gene Rearrangement
DNA
Genetic Recombination
Organism Cloning
Clone Cells
Recurrence
Polymerase Chain Reaction
Mutation

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. / Yamada, Masao; Hudson, S.; Tournay, O.; Bittenbender, S.; Shane, S. S.; Lange, B.; Tsujimoto, Y.; Caton, A. J.; Rovera, G.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, No. 13, 1989, p. 5123-5127.

Research output: Contribution to journalArticle

Yamada, Masao ; Hudson, S. ; Tournay, O. ; Bittenbender, S. ; Shane, S. S. ; Lange, B. ; Tsujimoto, Y. ; Caton, A. J. ; Rovera, G. / Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. In: Proceedings of the National Academy of Sciences of the United States of America. 1989 ; Vol. 86, No. 13. pp. 5123-5127.
@article{85a403e145e2411b8b99a029138dcd38,
title = "Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes",
abstract = "Approximately 80{\%} of hematopoietic malignancies of the B-cell lineage carry only one or two immunoglobulin heavy chain gene rearrangements indicating their clonal origin. These rearrangements due to the recombination of various variable, diversity, and joining regions of the heavy-chain gene segments during B-cell commitment result in a region called complementarity-determining region III (CDR-III). This region, which encompasses the diversity region of the heavy-chain segment, because of extensive somatic mutations, provides a DNA-encoded signature specific for each B-cell clone. CDR-III sequences were obtained from DNA of pre-B-cell acute lymphoblastic leukemia by using suitable primers and the polymerase chain reaction. The sequences were used to generate diagnostic probes that hybridized only to the amplified CDR-III of leukemic cells from which the sequences were derived. With these probes, leukemic cells could be detected when diluted 1:10,000 with other cells. By cloning the amplified CDR-III into recombinant libraries residual leukemic cells were accurately quantitated in bone-marrow samples from repeated relapses and remissions in one case of acute lymphoblastic leukemia. During a clinical remission lasting > 7 mo, malignant cells were present in marrow at > 1 per 1000 cells. These findings indicate that custom-made diagnostic probes will be useful in accurate quantitation of malignant cells in acute lymphoblastic leukemia patients in clinical remission and will allow investigation of the biological significance of low or high numbers of residual leukemic cells in evolution of that disease.",
author = "Masao Yamada and S. Hudson and O. Tournay and S. Bittenbender and Shane, {S. S.} and B. Lange and Y. Tsujimoto and Caton, {A. J.} and G. Rovera",
year = "1989",
language = "English",
volume = "86",
pages = "5123--5127",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "13",

}

TY - JOUR

T1 - Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes

AU - Yamada, Masao

AU - Hudson, S.

AU - Tournay, O.

AU - Bittenbender, S.

AU - Shane, S. S.

AU - Lange, B.

AU - Tsujimoto, Y.

AU - Caton, A. J.

AU - Rovera, G.

PY - 1989

Y1 - 1989

N2 - Approximately 80% of hematopoietic malignancies of the B-cell lineage carry only one or two immunoglobulin heavy chain gene rearrangements indicating their clonal origin. These rearrangements due to the recombination of various variable, diversity, and joining regions of the heavy-chain gene segments during B-cell commitment result in a region called complementarity-determining region III (CDR-III). This region, which encompasses the diversity region of the heavy-chain segment, because of extensive somatic mutations, provides a DNA-encoded signature specific for each B-cell clone. CDR-III sequences were obtained from DNA of pre-B-cell acute lymphoblastic leukemia by using suitable primers and the polymerase chain reaction. The sequences were used to generate diagnostic probes that hybridized only to the amplified CDR-III of leukemic cells from which the sequences were derived. With these probes, leukemic cells could be detected when diluted 1:10,000 with other cells. By cloning the amplified CDR-III into recombinant libraries residual leukemic cells were accurately quantitated in bone-marrow samples from repeated relapses and remissions in one case of acute lymphoblastic leukemia. During a clinical remission lasting > 7 mo, malignant cells were present in marrow at > 1 per 1000 cells. These findings indicate that custom-made diagnostic probes will be useful in accurate quantitation of malignant cells in acute lymphoblastic leukemia patients in clinical remission and will allow investigation of the biological significance of low or high numbers of residual leukemic cells in evolution of that disease.

AB - Approximately 80% of hematopoietic malignancies of the B-cell lineage carry only one or two immunoglobulin heavy chain gene rearrangements indicating their clonal origin. These rearrangements due to the recombination of various variable, diversity, and joining regions of the heavy-chain gene segments during B-cell commitment result in a region called complementarity-determining region III (CDR-III). This region, which encompasses the diversity region of the heavy-chain segment, because of extensive somatic mutations, provides a DNA-encoded signature specific for each B-cell clone. CDR-III sequences were obtained from DNA of pre-B-cell acute lymphoblastic leukemia by using suitable primers and the polymerase chain reaction. The sequences were used to generate diagnostic probes that hybridized only to the amplified CDR-III of leukemic cells from which the sequences were derived. With these probes, leukemic cells could be detected when diluted 1:10,000 with other cells. By cloning the amplified CDR-III into recombinant libraries residual leukemic cells were accurately quantitated in bone-marrow samples from repeated relapses and remissions in one case of acute lymphoblastic leukemia. During a clinical remission lasting > 7 mo, malignant cells were present in marrow at > 1 per 1000 cells. These findings indicate that custom-made diagnostic probes will be useful in accurate quantitation of malignant cells in acute lymphoblastic leukemia patients in clinical remission and will allow investigation of the biological significance of low or high numbers of residual leukemic cells in evolution of that disease.

UR - http://www.scopus.com/inward/record.url?scp=0011063097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0011063097&partnerID=8YFLogxK

M3 - Article

C2 - 2500663

AN - SCOPUS:0011063097

VL - 86

SP - 5123

EP - 5127

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 13

ER -